• MDV3100 (Enzalutamide) Research Workflows

  2026-09-11

  MDV3100 (Enzalutamide) provides a practical way to interrogate ligand-dependent androgen receptor signaling, apoptosis, localization, and resistance. This workflow extends established prostate cancer applications into carefully controlled AR-positive and ARv7-focused models, including exploratory triple-negative breast cancer research.

• Separating Growth Inhibition from Cancer Cell Death

  2026-09-10

  Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for interpreting proliferation arrest and cell killing as related but temporally and quantitatively distinct processes, with direct implications for assay design and cancer-model comparison.

• PLGA Nano-Adjuvant Enhances Mucosal Immunity in Chicks

  2026-09-10

  A 2026 Poultry Science study developed a PEI-modified, double-layer PLGA nanoparticle carrying Lagenaria siceraria polysaccharide and retinoic acid for H9N2 vaccine adjuvantation. The formulation combined sustained release with intestinal targeting and increased both systemic IgG and mucosal IgA responses, although protection, safety, and field performance require further validation.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-09-09

  BRD4770 is a G9a histone methyltransferase inhibitor that reduces intracellular H3K9 methylation and suppresses proliferation in PANC-1 cells. This article defines its mechanism, evidence boundaries, handling requirements, and use as a cancer biology research tool.

• Honokiol Workflows for Cancer Response Assays

  2026-09-09

  Use Honokiol to separate growth arrest, cell killing, NF-κB activity, and oxidative-stress responses instead of relying on a single viability endpoint. This practical workflow combines concentration-control, time-course design, and orthogonal assays for more interpretable cancer and inflammation research.

• LLY-507 SMYD2 Inhibitor: Research Workflows

  2026-09-08

  LLY-507 enables selective interrogation of SMYD2-dependent methylation, cancer cell proliferation inhibition, and stress-response signaling. This practical guide connects biochemical target engagement with cell-based validation and the renal fibrosis findings reported in a cisplatin injury model.

• Foretinib (GSK1363089) Assay Guide

  2026-09-08

  Build more informative cancer experiments with Foretinib by separating proliferation arrest, cell death, and motility rather than relying on a single viability endpoint. This practical guide connects dose design and orthogonal readouts to Met/VEGFR biology, migration studies, and translational metastasis models.

• Pazopanib Hydrochloride: Assay Reliability

  2026-09-07

  This practical guide shows how SKU A8347, Pazopanib Hydrochloride, can support more interpretable viability, proliferation, and cytotoxicity experiments. It connects the compound’s kinase selectivity and formulation data with evidence-based strategies for separating growth inhibition from cell death.

• Sunitinib B1045: Reliable Cancer Assay Workflows

  2026-09-07

  This scenario-driven guide explains how Sunitinib (SKU B1045) can improve experimental consistency in viability, proliferation, apoptosis, and resistance studies. It connects formulation, storage, assay design, and recent renal cell carcinoma evidence to practical laboratory decisions.

• HR-LCMS/MS Reveals a New Glabrol Source

  2026-09-05

  This study presents a streamlined HR-LCMS/MS-based dereplication workflow that connects autophagy activity in plant fractions with candidate bioactive metabolites. By screening medicinal plants in SH-SY5Y cells, the authors identified Astragalus dasyanthus as a previously unrecognized producer of the autophagy-inducing compound glabrol.

• Telatinib (BAY 57-9352) Assay Guide

  2026-09-04

  A scenario-based guide to using Telatinib (BAY 57-9352), SKU A8550, in viability, proliferation, cytotoxicity, invasion, and angiogenesis workflows. It connects reported kinase potency with practical DMSO handling, dose design, phenotype interpretation, combination testing, and product-selection criteria.

• Sunitinib: A Resistance-Aware Assay Guide

  2026-09-04

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with applications extending from angiogenesis studies to resistance biology. This guide translates TRIB3–SLC7A11/GPX4 findings into practical assay design for renal cell carcinoma and related tumor models.

• ATRX Loss Sensitizes Glioma to RTK Inhibitors

  2026-09-03

  The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support genotype-aware treatment evaluation, while also highlighting the need to distinguish cellular drug sensitivity from clinical efficacy.

• (S)-Mephenytoin in Organoid PK Assays

  2026-09-03

  Explore how (S)-Mephenytoin can qualify CYP2C19 activity in hiPSC-derived intestinal organoids. This article presents an assay-design framework that separates enzyme turnover from transport, maturation, and barrier effects.

• GZMK+ CD8+ T Cells Drive Recurrent Airway Inflammation

  2026-09-02

  The reference study identifies persistent GZMK-expressing CD8+ effector-memory T cell clones as a cellular basis for recurrent nasal polyps and related airway inflammation. By linking T cell clonality to GZMK-dependent complement cleavage, human tissue biomarkers, and intervention in a mouse asthma model, the work provides a mechanistic framework for studying inflammatory disease recurrence.

8364 records 2/558 page Previous Next 12345 下5页 Last page